KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Total Liabilities (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Total Liabilities data on record, last reported at $3.4 billion in Q4 2025.

  • For Q4 2025, Total Liabilities rose 12.27% year-over-year to $3.4 billion; the TTM value through Dec 2025 reached $3.4 billion, up 12.27%, while the annual FY2025 figure was $3.4 billion, 12.27% up from the prior year.
  • Total Liabilities reached $3.4 billion in Q4 2025 per EW's latest filing, up from $3.1 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.4 billion in Q3 2024 and bottomed at $2.4 billion in Q3 2022.
  • Average Total Liabilities over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2021.
  • Peak YoY movement for Total Liabilities: grew 27.09% in 2024, then dropped 8.71% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $2.7 billion in 2021, then decreased by 6.78% to $2.5 billion in 2022, then rose by 6.36% to $2.6 billion in 2023, then rose by 13.19% to $3.0 billion in 2024, then grew by 12.27% to $3.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $3.4 billion in Q4 2025, $3.1 billion in Q3 2025, and $2.9 billion in Q2 2025.